2021 Tumor Markers: Unlocking Mystery of Cancer-US, Europe, Japan-Suppliers Shares and Market Segment Forecasts by Tumor Marker and Country, Competitive Analysis, Technological Breakthroughs, Emerging Markets
LeadingMarketResearch's new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
The report is available by section, and can be customized to specific information needs and budget.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview
Supplier Shares, Sales and Volume Forecasts
Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
Contains 1,200 pages and 171 tables
The report is available by section, and can be customized to specific information needs and budget.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview
- Five-year test volume and sales projections by country.
- Comprehensive market segmentation analysis, including review of the market dynamics structure, size, growth and major suppliers by country.
- Estimated universe of laboratories performing cancer diagnostic testing by country.
- Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.
Supplier Shares, Sales and Volume Forecasts
- Sales and market shares of major cancer diagnostic product suppliers by individual test and country.
- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers
Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
Contains 1,200 pages and 171 tables
I. INTRODUCTION
II. WORLDWIDE MARKET OVERVIEW
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
ADA
B-Protein
PNP
5'-Nucleotidase
27. Oncogenes
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. Polypeptide Growth Factors
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
c. Sequencing
d. Microarrays/Biochips
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
VIII. FRANCE
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
IX. GERMANY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
X. ITALY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XI. JAPAN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XII. SPAIN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XIII. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XIV. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XV. COMPETITIVE PROFILES
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako
XVI. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGY AND APPLICATIONS
II. WORLDWIDE MARKET OVERVIEW
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
ADA
B-Protein
PNP
5'-Nucleotidase
27. Oncogenes
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. Polypeptide Growth Factors
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
c. Sequencing
d. Microarrays/Biochips
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
VIII. FRANCE
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
IX. GERMANY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
X. ITALY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XI. JAPAN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XII. SPAIN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XIII. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XIV. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers’ Sales And Market Shares
XV. COMPETITIVE PROFILES
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako
XVI. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGY AND APPLICATIONS